Please login to the form below

Not currently logged in
Email:
Password:

Zecuity

This page shows the latest Zecuity news and features for those working in and with pharma, biotech and healthcare.

Teva suspends migraine patch on burn reports

Teva suspends migraine patch on burn reports

Teva suspends migraine patch on burn reports. FDA issues safety alert and instigates investigation into Zecuity. ... Teva has not disclosed sales for Zecuity since its launch last September, but they are thought to be below $100m.

Latest news

  • Teva rolls out first migraine patch in US Teva rolls out first migraine patch in US

    The new Zecuity product is a disposable patch system worn for four-hours - on the upper arm or thigh - that delivers the widely-used migraine drug sumatriptan through the skin. ... The market research firm suggests that new formulations of triptans,

  • Endo's $2.2bn bid for Auxilium Pharma could thwart QLT deal Endo's $2.2bn bid for Auxilium Pharma could thwart QLT deal

    In the last few months it has also bought NuPathe for $105m - getting hold of migraine patch Zecuity (sumatriptan) - and in June offered $600m for generic player DAVA Pharmaceuticals.

  • FDA approves migraine headband FDA approves migraine headband

    This has meant focus has moved to device-type treatments, including Cefaly and sumatriptan skin patch Zecuity, marketed by pain specialist NuPathe, which is now at the centre of an attempted

  • Teva names Vigodman CEO and makes bid for NuPathe Teva names Vigodman CEO and makes bid for NuPathe

    NuPathe won US approval for its Zecuity (sumatriptan) migraine product last year, when it became the first transdermal patch cleared for the condition. ... Teva is also offering additional staged payments to shareholders if Zecuity sales top $100m, $300m

  • Endo builds pain management business Endo builds pain management business

    The move expands Endo's existing pain management business and brings NuPathe's lead product, the migraine treatment Zecuity, into the fold. ... Rajiv De Silva, president and CEO of Endo, confirmed that the company intends to launch Zecuity in the first

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    148. NuPathe/ Teva. Company acquisition. Includes key product Zecuity [sumatriptan] for migraine. ... JP and N. America. Further payments are due if Zecuity sales exceed a given threshold.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics